Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06185816

Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain

Led by Stanford University · Updated on 2026-04-24

95

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of non-invasive pulsed radiofrequency (NIPRF) therapy for treating chronic neuropathic pain that occurs after peripheral nerve injury. This type of pain often follows trauma or surgery and is commonly managed with nerve blocks, medications, physical therapy, neuromodulation, or surgery. The study aims to determine if NIPRF, delivered by an FDA-cleared device called the Stimpod, is an effective treatment option for this condition. Participants will be randomly assigned to receive either active NIPRF treatment or a non-active (placebo) device treatment. Those receiving active treatment will undergo three weekly sessions lasting about 20 minutes each. The device emits a high-frequency magnetic field via two electrodes, one placed on the skin and the other applied to the target nerve. The placebo device looks and sounds the same but does not deliver electrical stimulation. After the trial, participants in the placebo group will be offered three free active treatments. During the study, participants will be assessed for treatment response after three weeks of starting treatment. They will complete online and phone assessments to monitor pain levels and other outcomes. The study will track how well participants respond to the treatment and will monitor safety throughout the trial, which is sponsored by Stanford University and planned to continue until January 2029.

CONDITIONS

Brief Title

Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 or older with clinically diagnosed chronic neuropathic pain after peripheral nerve injury
  • Pain caused by peripheral nerve lesion with symptoms matching the affected nerve area
  • Positive response (at least 50% pain relief) to diagnostic nerve block at the suspected pain site
  • Persistent pain despite conservative therapy for at least 12 weeks
  • Stable analgesic medication dosage for at least 30 days, willing to avoid new pain medications for 3 weeks after randomization
  • Worst pain intensity of 5 or higher on a 0-10 Numeric Rating Scale at enrollment
  • English-speaking
  • Ability and willingness to complete online and phone assessments
Not Eligible

You will not qualify if you...

  • Inability to complete assessments due to education, cognitive, mental, or medical status
  • Cancer diagnosis or active malignant neoplasm
  • Painful polyneuropathy from metabolic, autoimmune, infectious, or toxic causes
  • Chronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis)
  • Peripheral vascular disease
  • Diabetic neuropathy
  • Presence of other active implantable devices (e.g., defibrillator, spinal cord stimulator)
  • Pregnancy, breastfeeding, or planning to conceive
  • Systemic or local infection at treatment sites
  • Interventional procedure or surgery to treat neuropathic pain in last 30 days (3 months for ablative treatment)
  • Epilepsy
  • Metal implants within the target treatment area of NIPRF

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 3 weeks

Participants receive non-invasive pulsed radiofrequency treatments or a placebo device once weekly for three weeks to treat neuropathic pain.

3 weekly visits (in-person)

Trial Site Locations

Total: 1 location

1

Stanford Pain Management Center

Redwood City, California, United States, 94063

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Bupivacaine-Lidocaine Combination Versus Bupivacaine Alone f...

Lower Extremity

Actively Recruiting

1 location

Surgical Treatments for Postamputation Pain Comparing Target...

Residual Limb Pain

Actively Recruiting

9 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here